1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014" provides data on the Plaque Psoriasis (Psoriasis Vulgaris) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Plaque Psoriasis (Psoriasis Vulgaris). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Plaque Psoriasis (Psoriasis Vulgaris). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Plaque Psoriasis (Psoriasis Vulgaris) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Plaque Psoriasis (Psoriasis Vulgaris) 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Plaque Psoriasis (Psoriasis Vulgaris) 33
Oct 16, 2014: New Analyses of Oral OTEZLA (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 33
Oct 10, 2014: Oral OTEZLA (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 34
Oct 08, 2014: Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 35
Oct 01, 2014: Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
The LEO Foundation 37
Clinical Trial Overview of The LEO Foundation 37
Johnson and Johnson 41
Clinical Trial Overview of Johnson and Johnson 41
Amgen Inc. 44
Clinical Trial Overview of Amgen Inc. 44
Pfizer Inc. 46
Clinical Trial Overview of Pfizer Inc. 46
AbbVie Inc. 48
Clinical Trial Overview of AbbVie Inc. 48
Maruho Co., Ltd. 50
Clinical Trial Overview of Maruho Co., Ltd. 50
Novartis AG 51
Clinical Trial Overview of Novartis AG 51
Galderma S.A. 53
Clinical Trial Overview of Galderma S.A. 53
Merck and Co., Inc. 55
Clinical Trial Overview of Merck and Co., Inc. 55
Astellas Pharma Inc. 56
Clinical Trial Overview of Astellas Pharma Inc. 56
Clinical Trial Overview of Top Institutes / Government 57
Guangdong Provincial Hospital of Traditional Chinese Medicine 57
Clinical Trial Overview of Guangdong Provincial Hospital of Traditional Chinese Medicine 57
University of California, San Francisco 58
Clinical Trial Overview of University of California, San Francisco 58
Mount Sinai Hospital 59
Clinical Trial Overview of Mount Sinai Hospital 59
Medical University of Vienna 60
Clinical Trial Overview of Medical University of Vienna 60
Rockefeller University 61
Clinical Trial Overview of Rockefeller University 61
Dresden University of Technology 62
Clinical Trial Overview of Dresden University of Technology 62
Tehran University of Medical Sciences 63
Clinical Trial Overview of Tehran University of Medical Sciences 63
Peking University People's Hospital 64
Clinical Trial Overview of Peking University People's Hospital 64
Chang Gung Memorial Foundation 65
Clinical Trial Overview of Chang Gung Memorial Foundation 65
Postgraduate Institute of Medical Education and Research 66
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 66
Five Key Clinical Profiles 67
Appendix 130
Abbreviations 130
Definitions 130
Research Methodology 131
Secondary Research 131
About GlobalData 132
Contact Us 132
Disclaimer 132
Source 132

List of Tables

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2014* 15
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2014* 18
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 29
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by The LEO Foundation, 2014* 37
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 41
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 44
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 46
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 48
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Maruho Co., Ltd., 2014* 50
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 51
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Galderma S.A., 2014* 53
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 55
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 56
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Guangdong Provincial Hospital of Traditional Chinese Medicine, 2014* 57
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 58
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mount Sinai Hospital, 2014* 59
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014* 60
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Rockefeller University, 2014* 61
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Dresden University of Technology, 2014* 62
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 63
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Peking University People's Hospital, 2014* 64
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Chang Gung Memorial Foundation, 2014* 65
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 66

List of Figures

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2014* 15
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2014* 18
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 28
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 29
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 30
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 131

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.